Comments

ARS Pharmaceuticals Stock Price, Quotes and Forecasts

Q: What sector and industry does ARS Pharmaceuticals (SPRY) operate in?

ARS Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

SPRYNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$13.15

0.262.02%

At close: -

$13.24

0.090.68%

After Hours: 7:03 PM EDT

Q4 2024 Earnings were released on Thu Mar 20th, before the market open

The most recent conference call was at 8:30 AM, 5 days ago Click to view past webcast

ARS Pharmaceuticals (SPRY) Forecast

News Earnings ARS Pharmaceuticals (SPRY) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

ARS Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SPRY | Benzinga

Explore ARS Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SPRY.

Open	$12.80
Close	$13.15
Volume / Avg.	1.79M / 1.54M
Day Range	$12.67 - $13.22
52 Wk Range	7.55 - 18.51
Market Cap	$1.30B
P/E Ratio	161.13
Dividend Yield	-
Exchange	NASDAQ
RSI	59
Short Interest	36.11%
Days to Cover	15.25

Recent News

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday

Avi Kapoor

FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment

FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

Vandana Singh

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Jan

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$12.80
Close	$13.15
Volume / Avg.	1.79M / 1.54M
Day Range	$12.67 - $13.22
52 Wk Range	7.55 - 18.51
Market Cap	$1.30B
P/E Ratio	161.13
Dividend Yield	-
Exchange	NASDAQ
RSI	59
Short Interest	36.11%
Days to Cover	15.25

About ARS Pharmaceuticals Inc

Sector

Health Care

Industry

Biotechnology

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentia...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy ARS Pharmaceuticals (SPRY) stock?

You can purchase shares of ARS Pharmaceuticals (NASDAQ:SPRY) through any online brokerage.

View our list of the best stock brokerages

Who are ARS Pharmaceuticals (SPRY) competitors?

Other companies in ARS Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), 89bio (NASDAQ:ETNB), Ascentage Pharma Group (NASDAQ:AAPG), Syndax Pharmaceuticals (NASDAQ:SNDX) and CareDx (NASDAQ:CDNA).

What is the forecast, or price target, for ARS Pharmaceuticals (SPRY) stock?

ARS Pharmaceuticals has a consensus price target of $24.67.

What is the current price for ARS Pharmaceuticals (SPRY)?

The stock price for ARS Pharmaceuticals (NASDAQ: SPRY) is $13.24 last updated March 25, 2025 at 7:03 PM EDT.

Does ARS Pharmaceuticals (SPRY) pay a dividend?

There are no upcoming dividends for ARS Pharmaceuticals.

When is ARS Pharmaceuticals (NASDAQ:SPRY) reporting earnings?

ARS Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 8, 2025.

Is ARS Pharmaceuticals (SPRY) going to split?

There is no upcoming split for ARS Pharmaceuticals.

What sector and industry does ARS Pharmaceuticals (SPRY) operate in?

ARS Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.